Bupropion interaction and antidepressant safety

Methylene blue and Wellbutrin: bupropion interaction and safety questions

Review methylene blue with Wellbutrin or bupropion using current label context for MAOI interactions, seizures, blood pressure, mood, G6PD deficiency, route differences, and pharmacy sourcing.

Educational guideUpdated July 17, 2026

A safer methylene blue and Wellbutrin review path

Name the clinical question first: treated depression, seasonal affective disorder, smoking-cessation care, off-label ADHD care, medication side effects, new brain fog, fatigue, or a general focus or longevity goal.

Identify every exact product. Record Wellbutrin or generic bupropion formulation, methylene-blue route and concentration, other brand names, pharmacy, prescribers, directions, and last-use dates.

Bring the current labels and complete medication list to the bupropion prescriber and pharmacist instead of relying on a seller interaction checker, social-media stack, or copied washout chart.

Review seizure and eating-disorder history, alcohol or sedative changes, blood pressure, mood and suicidal thoughts, bipolar or psychosis history, G6PD status, anemia, pregnancy context, and every prescription, OTC medicine, and supplement.

Reject research-use or dye-grade methylene blue, no-prescription bupropion, guaranteed mood or focus claims, self-directed antidepressant changes, and websites that hide the clinician or dispensing pharmacy.

Direct answer

Do not add low-dose oral methylene blue to Wellbutrin or another bupropion product without coordinated prescriber and pharmacist review. The current Wellbutrin XL label contraindicates starting it in a patient being treated with reversible monoamine oxidase inhibitors such as linezolid or intravenous methylene blue. Current PROVAYBLUE injection labeling separately names bupropion among medicines to avoid with intravenous methylene blue because of potentially serious central-nervous-system reactions, including serotonin syndrome. Those statements are product- and route-specific: they do not create a universal do-it-yourself washout schedule for compounded oral methylene blue. They do create a strong stop-and-review signal. Do not combine the products or stop, skip, taper, or restart Wellbutrin to qualify for methylene blue; ask the bupropion prescriber and pharmacist to review the exact formulations, route, concentration, source, timing, full medication list, seizure risk, blood pressure, and mental-health history.

Different treatment roles

Wellbutrin treats specific mood conditions; oral methylene blue does not

Wellbutrin XL is an extended-release bupropion antidepressant. Its current label lists treatment of major depressive disorder and prevention of seasonal major depressive episodes in people with seasonal affective disorder. Other bupropion formulations and brands can have different labeled uses, release profiles, and instructions; bupropion is also used in some clinician-managed off-label contexts. FDA-approved methylene-blue injections treat acquired methemoglobinemia. Low-dose oral methylene blue marketed for focus, fatigue, mitochondrial support, mood, or longevity is a different route and an off-label or compounded pathway—not an FDA-approved antidepressant, ADHD medicine, or Wellbutrin substitute.

Do not replace, pause, reduce, or restart bupropion because a post calls methylene blue a natural antidepressant, nootropic, mitochondrial enhancer, or safer focus medicine.
New or worsening low mood, inattention, fatigue, or brain fog can reflect depression, bipolar disorder, sleep loss, sleep apnea, thyroid disease, anemia, substance use, medication effects, or another condition that needs diagnosis-first care.
Product identity matters. Immediate-release, sustained-release, and extended-release bupropion products are not automatically interchangeable, and smoking-cessation products should not be collapsed into the Wellbutrin XL mood label.

MAOI and interaction boundary

The current labels create a stop-and-review signal—not a home washout plan

The current Wellbutrin XL label contraindicates starting the product in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue and describes increased hypertensive-reaction risk with MAOIs. Current PROVAYBLUE injection labeling says literature reports suggest methylene blue is a potent reversible monoamine oxidase inhibitor and explicitly includes bupropion among medicines to avoid with intravenous PROVAYBLUE because of potentially serious central-nervous-system reactions. These approved labels address named products and routes. They do not establish a universal oral-methylene-blue risk estimate, safe concentration, or self-directed interval for compounded products.

Do not combine the products or convert a label interval for MAOI antidepressants or intravenous methylene blue into instructions for stopping, starting, tapering, or restarting oral methylene blue or bupropion.
Disclose SSRIs, SNRIs, MAOIs, tricyclics, mirtazapine, buspirone, linezolid, triptans, opioids, dextromethorphan, stimulants, decongestants, levodopa, amantadine, caffeine or energy products, nicotine, sleep medicines, alcohol, cannabis, and nootropic supplements.
If methylene blue is medically necessary in an approved acute-care setting, the treating team—not an online seller—should manage the medication plan, monitoring, and emergency context.

Bupropion-specific risks

Seizure, blood-pressure, mood, and formulation history change the review

Current Wellbutrin XL labeling carries a boxed warning about suicidal thoughts and behaviors in children, adolescents, and young adults taking antidepressants and calls for monitoring in patients of all ages when treatment begins or changes. It also addresses dose-related seizure risk, blood-pressure increases, activation of mania or hypomania, psychosis and other neuropsychiatric reactions, and CYP2D6 drug interactions. The label lists contraindications that include seizure disorder, current or prior bulimia or anorexia nervosa, and abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs. These risks require the prescribing clinician; they are not reasons to improvise a lower dose or switch products.

Review seizure history, head injury, eating-disorder history, heavy alcohol use, recent alcohol or sedative reduction, diabetes medicines, other seizure-threshold-lowering drugs, blood pressure, and heart symptoms.
Review suicidal thoughts, worsening depression, agitation, panic, major behavior change, bipolar disorder, mania, psychosis, aggression, and sleep disruption, especially after a bupropion start or change.
Disclose medicines affected by CYP2D6 inhibition, including certain antidepressants, antipsychotics, beta-blockers, and antiarrhythmics, so the prescriber and pharmacist can assess the complete regimen rather than one pair in isolation.

Methylene-blue safety and sourcing

Route, G6PD status, serotonergic medicines, and pharmacy identity matter

Current methylene-blue injection labeling is route-specific and addresses serotonin syndrome, hypersensitivity, G6PD deficiency, and hemolytic anemia. It does not approve low-dose oral methylene blue for depression, ADHD, focus, fatigue, or bupropion replacement. Compounded preparations are not FDA-approved finished drug products. Search results may mix licensed care with aquarium or dye products, research chemicals, vague “pharmaceutical grade” liquids, copied stacks, and sellers that omit medication screening.

Review known or possible G6PD deficiency, anemia or hemolysis, dark urine or jaundice, pregnancy or breastfeeding, kidney or liver disease, dye reactions, exact route, concentration, and pharmacy source.
Urgent evaluation may be needed for suicidal intent, seizure, severe agitation or hallucinations, high fever, marked rigidity, rapidly worsening confusion, fainting, chest pain, severe headache with major blood-pressure symptoms, dark urine, or jaundice.
Avoid research-use, laboratory, aquarium, industrial, or dye-grade methylene blue and any bupropion seller that bypasses a prescription, mental-health review, interaction screening, or follow-up.

Patient safety checklist

Questions to ask before considering methylene blue with Wellbutrin or bupropion

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

Am I treating diagnosed depression, seasonal affective disorder, smoking-cessation needs, or ADHD, or trying to solve new brain fog, fatigue, sleepiness, low motivation, medication side effects, or a general productivity or longevity goal?

✓

Which exact bupropion and methylene-blue products, formulations, routes, concentrations, labels, pharmacies, prescribers, directions, and last-use dates apply?

✓

Has the bupropion prescriber reviewed the current MAOI contraindication and route-specific methylene-blue label instead of relying on a seller interaction or washout chart?

✓

Have seizure, head-injury, eating-disorder, alcohol, benzodiazepine, barbiturate, antiepileptic-drug, diabetes, blood-pressure, heart, kidney, liver, pregnancy, and breastfeeding history been reviewed?

✓

Have mood and suicidal thoughts, bipolar or psychosis history, agitation, anxiety, sleep, substance use, and recent medication changes been reviewed by the clinician managing bupropion?

✓

Have I disclosed every antidepressant, opioid, migraine medicine, cough product, antibiotic such as linezolid, stimulant, decongestant, CYP2D6-sensitive medicine, caffeine product, nicotine product, supplement, and nootropic?

✓

Do G6PD deficiency, anemia or hemolysis history, dark urine or jaundice, or a prior dye reaction change the methylene-blue discussion?

✓

Who will coordinate the bupropion prescriber, pharmacist, primary-care or mental-health clinician, and any Peptide12 clinician reviewing low-dose oral methylene blue?

✓

What is the measurable goal, follow-up interval, blood-pressure plan, mood and sleep monitoring plan, side-effect plan, stop rule, and urgent-care threshold?

FAQs

Short answers for patients

Can I take methylene blue with Wellbutrin or bupropion?

Do not combine them without coordinated prescriber and pharmacist review. The current Wellbutrin XL label contraindicates starting it in a patient treated with reversible MAOIs such as intravenous methylene blue, and current PROVAYBLUE injection labeling explicitly names bupropion among drugs to avoid with intravenous methylene blue. The exact formulations, methylene-blue route and source, other medicines, seizure risk, blood pressure, and reason for use all matter.

Can methylene blue replace Wellbutrin for depression or focus?

No evidence or FDA label supports low-dose oral methylene blue as a Wellbutrin replacement for major depressive disorder, seasonal affective disorder, ADHD, or focus. Do not stop or reduce bupropion without the prescribing clinician. Mood or attention symptoms should be reviewed by diagnosis, response, side effects, sleep, substance use, medical causes, and mental-health safety.

Should I stop Wellbutrin before trying oral methylene blue?

Do not stop, skip, taper, or restart bupropion on your own. Current label language for Wellbutrin XL, MAOI antidepressants, and intravenous methylene blue does not create a self-directed oral-methylene-blue schedule. Ask the bupropion prescriber and pharmacist for product-specific instructions; abrupt or uncoordinated antidepressant changes can destabilize care.

Is bupropion an SSRI or a standard serotonergic antidepressant?

Bupropion is an aminoketone antidepressant and is not an SSRI. That distinction does not make the combination automatically safe: current PROVAYBLUE labeling names bupropion specifically, and Wellbutrin XL labeling addresses reversible MAOIs such as intravenous methylene blue. Use the current product labels and a pharmacist review rather than a simplified serotonin-only checklist.

Why does seizure history matter in this comparison?

Current Wellbutrin XL labeling describes dose-related seizure risk and lists several seizure-related contraindications and risk factors. A clinician should review seizure history, eating disorders, head injury, alcohol or sedative changes, diabetes medicines, and other drugs that lower seizure threshold. Do not change a bupropion dose or formulation to make a methylene-blue stack seem safer.

Is oral methylene blue FDA-approved for depression, ADHD, or focus?

No. FDA-approved methylene-blue injections treat acquired methemoglobinemia. Low-dose oral methylene blue discussed for mood, focus, fatigue, mitochondrial support, or longevity is off-label or compounded and is not FDA-approved for depression, ADHD, productivity, or bupropion replacement.

What online seller red flags should I avoid?

Avoid no-prescription bupropion, research-use or dye-grade methylene blue sold for ingestion, guaranteed antidepressant or focus claims, copied washout or stack charts, instructions to hide one product from a prescriber, vague concentrations, hidden pharmacy identity, and sellers without seizure, blood-pressure, mood, interaction, or follow-up screening.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

DailyMed: Wellbutrin XL (bupropion hydrochloride extended-release) prescribing information — published February 2026 MedlinePlus: Bupropion drug information DailyMed: PROVAYBLUE (methylene blue) injection prescribing information openFDA: Current PROVAYBLUE label data, boxed warning and drug interactions MedlinePlus Genetics: Glucose-6-phosphate dehydrogenase deficiency FDA: Compounding and the FDA — Questions and Answers Peptide12: Methylene blue and antidepressants Peptide12: Methylene blue medication interactions Peptide12: Methylene blue vs atomoxetine Peptide12: Methylene blue vs Adderall Peptide12: ADHD and stimulant medication review Peptide12: Methylene blue safety guide Peptide12: When in-person care is needed Peptide12: Low-dose oral methylene blue Peptide12: How online peptide therapy works